Israel: Experimental drugs can cure 100% of severely ill patients with COVID-19
- EPA Announces First-Ever Regulation for “Forever Chemicals” in Drinking Water
- Kochi University pioneers outpatient bladder cancer treatment using semiconductor lasers
- ASPEN 2024: Nutritional Therapy Strategies for Cancer and Critically Ill Patients
- Which lung cancer patients can benefit from neoadjuvant immunotherapy?
- Heme Iron Absorption: Why Meat Matters for Women’s Iron Needs
- “Miracle Weight-loss Drug” Semaglutide Is Not Always Effective
Israel: Experimental drugs can cure 100% of severely ill patients with COVID-19
- Red Yeast Rice Scare Grips Japan: Over 114 Hospitalized and 5 Deaths
- Long COVID Brain Fog: Blood-Brain Barrier Damage and Persistent Inflammation
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
Israel: Experimental drugs can cure 100% of severely ill patients with COVID-19. The magic drug is here?
According to a foreign media report on December 22, the Israeli biotechnology company Amorphical announced on the same day that in the phase 2 clinical trial of the company’s COVID-19 pneumonia drug “Amor-18”, 18 patients were treated for moderate and severe COVID-19 pneumonia.
All patients recovered and were discharged from the hospital within a few days. Of the 19 patients who received placebo-controlled treatment, 6 were transferred to the intensive care unit and 2 died.
In clinical trials, 18 patients with moderate and severe COVID-19 pneumonia recovered and were discharged from the hospital within a few days
According to reports, the trial was conducted at the Zief Medical Center in Zefat, Israel, and was led by Dr. Kamal Abu Jabbar and Dr. Nashat Abu Saleh, directors of the COVID-19 virus department of the hospital.
As part of the humanitarian care, two other patients with very serious conditions also took the drug and both recovered and were discharged from the hospital. Dr. Saleh said: “Because the patient who received the medication recovered within a few days and was discharged from the hospital and returned home, it was 100% successful.”
Amor-18, using amorphous calcium carbonate (ACC) as the main ingredient, is taken orally or inhaled through aerosol. According to Amorphical, ACC has the ability to adjust the acid pH around each cell.
These changes affect the ability of the coronavirus to penetrate cells and replicate, so the drug can prevent the spread of the virus, thereby preventing the patient’s condition from getting worse.
Amorphical claims that amorphous calcium carbonate (ACC) has great potential in treating diseases
The company’s CEO Yossi Ben added that Amor-18 has “anti-inflammatory, safe, effective, easy to use and other advantages”, and it can fight against all new coronavirus variants including Delta and Omicron. The entire SARS virus family.
Amorphical said that it has studied ACC in five other clinical trials and has proven its safety in the treatment of various diseases. In the company’s previous research, the adjustment of pH by ACC nanoparticles caused the metabolism of cancer cells to shift to oxidative phosphorylation, reducing the growth rate of tumors, reducing the ability of cancer cells to invade and metastasize, and enhance the immune system’s ability to defeat tumors.
In addition, ACC also has great potential in reversing bone degeneration, accelerating repairs that affect the verification of autoimmune diseases, reducing pain, improving fertility and improving athletic performance.
Screenshots of public information on clinical trials
According to public information, Amorphical initiated a study on the use of ACC to treat COVID-19 pneumonia in February this year, and submitted a formal clinical trial application on May 19. “We are very excited about the results of the clinical trial.
It brings real hope to people infected with the coronavirus in Israel and around the world, especially with the rise of the fifth wave of the epidemic and the rapid spread of the Omicron variant. , This is particularly encouraging.” Yossi Ben said.
According to reports, Israel’s Zief Medical Center, Shamir Medical Center, Kaplan and Tel Aviv Mahani Hayeswa Medical Center are already conducting a larger trial. In the near future, this drug will also be tested in other countries.
At present, seven hospitals in Brazil have announced that they will participate, and other medical centers in Europe and the United States are expected to join soon.
Israel: Experimental drugs can cure 100% of severely ill patients with COVID-19
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
